Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Lung Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 118 articles: HTML format

Single Articles

September 2020
1. BAIZE N, Monnet I, Greillier L, Geier M, et al
   Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
   Lancet Oncol. 2020;21:1224-1233.
   PubMed     Abstract available
   
   
   
2. ARRIETA O, Lara-Mejia L, Zatarain-Barron ZL
   Carboplatin plus etoposide or topotecan for small-cell lung cancer.
   Lancet Oncol. 2020;21:1132-1134.
   PubMed    
   
   
   July 2020
3. MARINGE C, Spicer J, Morris M, Purushotham A, et al
   The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.
   Lancet Oncol. 2020 Jul 20. pii: S1470-2045(20)30388.
   PubMed     Abstract available
   
   
   
4. RAMELLA S, D'Angelillo RM
   Proton beam or photon beam radiotherapy in the treatment of non-small-cell lung cancer.
   Lancet Oncol. 2020;21:873-875.
   PubMed    
   
   
   June 2020
5. NESTLE U, Schimek-Jasch T, Konig J
   Less is more? Imaging-based target volume reduction - Authors' reply.
   Lancet Oncol. 2020;21:e303.
   PubMed    
   
   
   
6. BLAIS E, Troussier I
   Less is more? Imaging-based target volume reduction.
   Lancet Oncol. 2020;21:e302.
   PubMed    
   
   
   May 2020
7. ROSELL R, Ito M
   Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer.
   Lancet Oncol. 2020 May 7. pii: S1470-2045(20)30146.
   PubMed    
   
   
   
8. SHU CA, Gainor JF, Awad MM, Chiuzan C, et al
   Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
   Lancet Oncol. 2020 May 7. pii: S1470-2045(20)30140.
   PubMed     Abstract available
   
   
   
9. GOLDBERG SB, Schalper KA, Gettinger SN, Mahajan A, et al
   Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
   Lancet Oncol. 2020;21:655-663.
   PubMed     Abstract available
   
   
   April 2020
10. BARLESI F, Tomasini P
    Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors.
    Lancet Oncol. 2020 Apr 3. pii: S1470-2045(20)30207.
    PubMed    
    
    
    March 2020
11. TRIGO J, Subbiah V, Besse B, Moreno V, et al
    Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
    Lancet Oncol. 2020 Mar 27. pii: S1470-2045(20)30068.
    PubMed     Abstract available
    
    
    
12. ARRIETA O, Zatarain-Barron ZL, Cardona AF
    New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer.
    Lancet Oncol. 2020 Mar 27. pii: S1470-2045(20)30097.
    PubMed    
    
    
    
13. REALE ML, Di Maio M
    Quality of life in patients with lung cancer: the way forward.
    Lancet Oncol. 2020 Mar 23. pii: S1470-2045(20)30151.
    PubMed    
    
    
    
14. KOLLER M, Shamieh O, Hjermstad MJ, Hornslien K, et al
    Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.
    Lancet Oncol. 2020 Mar 23. pii: S1470-2045(20)30093.
    PubMed     Abstract available
    
    
    
15. NESTLE U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, et al
    Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Lancet Oncol. 2020 Mar 12. pii: S1470-2045(20)30013.
    PubMed     Abstract available
    
    
    
16. FAIVRE-FINN C
    Less is more in radiotherapy target volume planning: lessons from the PET-plan trial.
    Lancet Oncol. 2020 Mar 12. pii: S1470-2045(20)30108.
    PubMed    
    
    
    February 2020
17. GARASSINO MC, Gadgeel S, Esteban E, Felip E, et al
    Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-contro
    Lancet Oncol. 2020 Feb 6. pii: S1470-2045(19)30801.
    PubMed     Abstract available
    
    
    
18. FUNG AS, Leighl NB
    Advancing the systemic therapy of lung cancer: quality or quantity?
    Lancet Oncol. 2020 Feb 6. pii: S1470-2045(20)30076.
    PubMed    
    
    
    
19. SEQUIST LV, Han JY, Ahn MJ, Cho BC, et al
    Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Lancet Oncol. 2020 Feb 3. pii: S1470-2045(19)30785.
    PubMed     Abstract available
    
    
    
20. SCHMID S, Fruh M, Peters S
    Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
    Lancet Oncol. 2020 Feb 3. pii: S1470-2045(19)30859.
    PubMed    
    
    
    
21. LASSEN U
    Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours.
    Lancet Oncol. 2020;21:193-194.
    PubMed    
    
    
    
22. MIAN I, Padiernos E, Hassan R, Ghafoor A, et al
    Orbital metastases from malignant mesothelioma.
    Lancet Oncol. 2020;21:e117.
    PubMed    
    
    
    January 2020
23. DE GOOIJER CJ, Burgers JA
    Tumour Treating Fields for mesothelioma.
    Lancet Oncol. 2020;21:e9.
    PubMed    
    
    
    
24. BARBARINO M, Bottaro M, Luzzi L, Giordano A, et al
    Tumour Treating Fields for mesothelioma.
    Lancet Oncol. 2020;21:e8.
    PubMed    
    
    
    
25. CERESOLI GL, Gianoncelli L, Grosso F
    Tumour Treating Fields for mesothelioma - Authors' reply.
    Lancet Oncol. 2020;21:e10.
    PubMed    
    
    
    
26. GOURD E
    Osimertinib for leptomeningeal metastases in NSCLC.
    Lancet Oncol. 2020;21:e17.
    PubMed    
    
    
    
27. GOURD E
    Overall survival with osimertinib in untreated NSCLC.
    Lancet Oncol. 2020;21:e15.
    PubMed    
    
    
    December 2019
28. DRILON A, Siena S, Dziadziuszko R, Barlesi F, et al
    Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30690.
    PubMed     Abstract available
    
    
    October 2019
29. DURUISSEAUX M
    Lorlatinib: a new treatment option for ROS1-positive lung cancer.
    Lancet Oncol. 2019 Oct 25. pii: S1470-2045(19)30716.
    PubMed    
    
    
    
30. SHAW AT, Solomon BJ, Chiari R, Riely GJ, et al
    Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
    Lancet Oncol. 2019 Oct 25. pii: S1470-2045(19)30655.
    PubMed     Abstract available
    
    
    
31. HUI R, Ozguroglu M, Villegas A, Daniel D, et al
    Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
    Lancet Oncol. 2019 Oct 7. pii: S1470-2045(19)30519.
    PubMed     Abstract available
    
    
    
32. ANOTA A, Westeel V
    Quality of life with durvalumab in stage III non-small-cell lung cancer.
    Lancet Oncol. 2019 Oct 7. pii: S1470-2045(19)30643.
    PubMed    
    
    
    
33. NAKAGAWA K, Garon EB, Seto T, Nishio M, et al
    Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Oct 4. pii: S1470-2045(19)30634.
    PubMed     Abstract available
    
    
    
34. ROSELL R, Pedraz-Valdunciel C
    Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?
    Lancet Oncol. 2019 Oct 4. pii: S1470-2045(19)30636.
    PubMed    
    
    
    
35. AHN MJ, Han JY, Lee KH, Kim SW, et al
    Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
    Lancet Oncol. 2019 Oct 3. pii: S1470-2045(19)30504.
    PubMed     Abstract available
    
    
    
36. FIERO MH, Roydhouse JK, Vallejo J, King-Kallimanis BL, et al
    US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017.
    Lancet Oncol. 2019;20:e582-e589.
    PubMed     Abstract available
    
    
    September 2019
37. CAPPUZZO F, West H
    Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2019;20:e467.
    PubMed    
    
    
    
38. UPRETY D
    Chemoimmunotherapy for stage IV non-small-cell lung cancer.
    Lancet Oncol. 2019;20:e466.
    PubMed    
    
    
    August 2019
39. DAS M
    Nelfinavir with concurrent chemoradiotherapy in NSCLC.
    Lancet Oncol. 2019 Aug 30. pii: S1470-2045(19)30567.
    PubMed    
    
    
    
40. ANTONIA SJ, Borghaei H, Ramalingam SS, Horn L, et al
    Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
    Lancet Oncol. 2019 Aug 14. pii: S1470-2045(19)30407.
    PubMed     Abstract available
    
    
    
41. SOUQUET PJ, Couraud S
    Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer.
    Lancet Oncol. 2019 Aug 14. pii: S1470-2045(19)30508.
    PubMed    
    
    
    July 2019
42. HERBST RS, Arkenau HT, Santana-Davila R, Calvo E, et al
    Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Lancet Oncol. 2019 Jul 10. pii: S1470-2045(19)30458.
    PubMed     Abstract available
    
    
    June 2019
43. LUO YH, Luo L, Wampfler JA, Wang Y, et al
    5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.
    Lancet Oncol. 2019 Jun 26. pii: S1470-2045(19)30329.
    PubMed     Abstract available
    
    
    
44. BERG CD
    Improving selection of individuals into lung cancer screening programmes.
    Lancet Oncol. 2019 Jun 26. pii: S1470-2045(19)30411.
    PubMed    
    
    
    May 2019
45. LI Y, Wu YL
    The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer.
    Lancet Oncol. 2019 May 20. pii: S1470-2045(19)30148.
    PubMed    
    
    
    
46. WEST H, McCleod M, Hussein M, Morabito A, et al
    Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3
    Lancet Oncol. 2019 May 20. pii: S1470-2045(19)30167.
    PubMed     Abstract available
    
    
    April 2019
47. JIANG Z, Li W, Hu X, Zhang Q, et al
    Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Apr 26. pii: S1470-2045(19)30164.
    PubMed     Abstract available
    
    
    
48. SAITO H, Fukuhara T, Furuya N, Watanabe K, et al
    Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
    Lancet Oncol. 2019 Apr 8. pii: S1470-2045(19)30035.
    PubMed     Abstract available
    
    
    February 2019
49. ALSHAFA F, Palma D
    CHISELing a path forward in the treatment of early-stage non-small-cell lung cancer.
    Lancet Oncol. 2019 Feb 12. pii: S1470-2045(18)30953.
    PubMed    
    
    
    
50. BALL D, Mai GT, Vinod S, Babington S, et al
    Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Lancet Oncol. 2019 Feb 12. pii: S1470-2045(18)30896.
    PubMed     Abstract available
    
    
    November 2018
51. SOLOMON BJ, Besse B, Bauer TM, Felip E, et al
    Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Lancet Oncol. 2018 Nov 6. pii: S1470-2045(18)30649.
    PubMed     Abstract available
    
    
    September 2018
52. ROSELL R, Karachaliou N
    Avelumab in non-small-cell lung cancer.
    Lancet Oncol. 2018 Sep 21. pii: S1470-2045(18)30683.
    PubMed    
    
    
    
53. BARLESI F, Vansteenkiste J, Spigel D, Ishii H, et al
    Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
    Lancet Oncol. 2018 Sep 21. pii: S1470-2045(18)30673.
    PubMed     Abstract available
    
    
    
54. BLACKHALL F, Frese KK, Simpson K, Kilgour E, et al
    Will liquid biopsies improve outcomes for patients with small-cell lung cancer?
    Lancet Oncol. 2018;19:e470-e481.
    PubMed     Abstract available
    
    
    August 2018
55. HIOM SC, Kumar HS, Swanton C, Baldwin DR, et al
    Lung cancer in the UK: addressing geographical inequality and late diagnosis.
    Lancet Oncol. 2018;19:1015-1017.
    PubMed    
    
    
    July 2018
56. GLANVILLE AR, Wilson BE
    Lung transplantation for non-small cell lung cancer and multifocal bronchioalveolar cell carcinoma.
    Lancet Oncol. 2018;19:e351-e358.
    PubMed     Abstract available
    
    
    
57. BAAS P, Burgers S
    Malignant pleural effusions: will PROMISE make its name true?
    Lancet Oncol. 2018;19:853-855.
    PubMed    
    
    
    
58. LUCAS C
    Miracle mineral or mesothelioma: cancer and asbestos in the USA.
    Lancet Oncol. 2018;19:868.
    PubMed    
    
    
    June 2018
59. GOURD E
    Lung cancer incidence higher in US women than men.
    Lancet Oncol. 2018 Jun 1. pii: S1470-2045(18)30422.
    PubMed    
    
    
    
60. GREGORC V, Gaafar RM, Favaretto A, Grossi F, et al
    NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet Oncol. 2018;19:799-811.
    PubMed     Abstract available
    
    
    April 2018
61. ROLFO C, Smits ELJ
    Combining top-ranked immunotherapeutics in lung cancer.
    Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30186.
    PubMed    
    
    
    
62. WRANGLE JM, Velcheti V, Patel MR, Garrett-Mayer E, et al
    ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
    Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30148.
    PubMed     Abstract available
    
    
    March 2018
63. LIN JJ, Gainor JF
    ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
    Lancet Oncol. 2018 Mar 12. pii: S1470-2045(18)30160.
    PubMed    
    
    
    
64. GARASSINO MC, Cho BC, Kim JH, Mazieres J, et al
    Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Lancet Oncol. 2018 Mar 12. pii: S1470-2045(18)30144.
    PubMed     Abstract available
    
    
    
65. FIELD JK, Heuvelmans MA, Devaraj A, Heussel CP, et al
    Low-dose CT for lung cancer screening - Authors' reply.
    Lancet Oncol. 2018;19:e135-e136.
    PubMed    
    
    
    
66. BACH PB, Brawley OW, Silvestri GA
    Low-dose CT for lung cancer screening.
    Lancet Oncol. 2018;19:e133-e134.
    PubMed    
    
    
    
67. RUANO-RAVINA A, Perez-Rios M, Casan-Clara P, Provencio-Pulla M, et al
    Low-dose CT for lung cancer screening.
    Lancet Oncol. 2018;19:e131-e132.
    PubMed    
    
    
    
68. WU YL, Zhong WZ
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2018;19:e127.
    PubMed    
    
    
    
69. ROSELL R, Karachaliou N
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e126.
    PubMed    
    
    
    
70. MA JA, Jiang S, Hu C, Xie Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e125.
    PubMed    
    
    
    
71. WU F, Liu X, Ma JA, Gao Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e124.
    PubMed    
    
    
    
72. SCHERPEREEL A, Wallyn F, Albelda SM, Munck C, et al
    Novel therapies for malignant pleural mesothelioma.
    Lancet Oncol. 2018;19:e161-e172.
    PubMed     Abstract available
    
    
    February 2018
73. ILEANA-DUMBRAVA E, Subbiah V
    Autoimmune hypophysitis.
    Lancet Oncol. 2018;19:e123.
    PubMed    
    
    
    January 2018
74. CHENG H, Perez-Soler R
    Leptomeningeal metastases in non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e43-e55.
    PubMed     Abstract available
    
    
    
75. WU YL, Mok TS
    Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply.
    Lancet Oncol. 2018;19:e5.
    PubMed    
    
    
    
76. ADDEO A
    Dacomitinib in NSCLC: a positive trial with little clinical impact.
    Lancet Oncol. 2018;19:e4.
    PubMed    
    
    
    
77. NG TL, Camidge DR
    Lung cancer's real adjuvant EGFR targeted therapy questions.
    Lancet Oncol. 2018;19:15-17.
    PubMed    
    
    
    
78. PIRKER R
    EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation.
    Lancet Oncol. 2018;19:10-12.
    PubMed    
    
    
    
79. STIRRUPS R
    Osimertinib improves progression-free survival in NSCLC.
    Lancet Oncol. 2018;19:e10.
    PubMed    
    
    
    
80. GOURD E
    Durvalumab boosts progression-free survival in NSCLC.
    Lancet Oncol. 2018;19:e11.
    PubMed    
    
    
    
81. ZHONG WZ, Wang Q, Mao WM, Xu ST, et al
    Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Lancet Oncol. 2018;19:139-148.
    PubMed     Abstract available
    
    
    
82. HERBST RS, Redman MW, Kim ES, Semrad TJ, et al
    Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Lancet Oncol. 2018;19:101-114.
    PubMed     Abstract available
    
    
    December 2017
83. OUDKERK M, Devaraj A, Vliegenthart R, Henzler T, et al
    European position statement on lung cancer screening.
    Lancet Oncol. 2017;18:e754-e766.
    PubMed     Abstract available
    
    
    
84. EMERY JD, Mitchell PL
    Lung cancer in Asian women and health system implications for Australia.
    Lancet Oncol. 2017;18:1570-1571.
    PubMed    
    
    
    
85. BRAHMER JR, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Lancet Oncol. 2017;18:1600-1609.
    PubMed     Abstract available
    
    
    
86. FEROLLA P, Brizzi MP, Meyer T, Mansoor W, et al
    Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2017;18:1652-1664.
    PubMed     Abstract available
    
    
    November 2017
87. WEISS J
    Bevacizumab in adjuvant treatment of non-small-cell lung cancer.
    Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30843.
    PubMed    
    
    
    
88. WAKELEE HA, Dahlberg SE, Keller SM, Tester WJ, et al
    Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
    Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30691.
    PubMed     Abstract available
    
    
    October 2017
89. SHAW AT, Felip E, Bauer TM, Besse B, et al
    Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Lancet Oncol. 2017 Oct 23. pii: S1470-2045(17)30680.
    PubMed     Abstract available
    
    
    
90. DE KONING HJ
    Lung cancer screening and its continuous risk assessment.
    Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30730.
    PubMed    
    
    
    
91. TAMMEMAGI MC, Schmidt H, Martel S, McWilliams A, et al
    Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30597.
    PubMed     Abstract available
    
    
    
92. FAIVRE-FINN C, Ryder WD, Blackhall F
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply.
    Lancet Oncol. 2017;18:e556.
    PubMed    
    
    
    
93. EZE C, Roengvoraphoj O, Dantes M, Manapov F, et al
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e555.
    PubMed    
    
    
    
94. MITIN T, Farrell M, Holland J, Cetnar J, et al
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e554.
    PubMed    
    
    
    
95. ZENG H, Yu J, Yuan S
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e553.
    PubMed    
    
    
    
96. VAN ZANDWIJK N, Pavlakis N, Kao SC, Linton A, et al
    Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    Lancet Oncol. 2017;18:1386-1396.
    PubMed     Abstract available
    
    
    
97. PAVEL ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, et al
    Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase
    Lancet Oncol. 2017;18:1411-1422.
    PubMed     Abstract available
    
    
    September 2017
98. BRUECKL WM
    Treatment choice in EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30684.
    PubMed    
    
    
    
99. WU YL, Cheng Y, Zhou X, Lee KH, et al
    Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30608.
    PubMed     Abstract available
    
    
    
100. PLANCHARD D, Smit EF, Groen HJM, Mazieres J, et al
     Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
     Lancet Oncol. 2017 Sep 8. pii: S1470-2045(17)30679.
     PubMed     Abstract available
     
     
     
101. PERROT M, Wu L, Wu M, Cho BCJ, et al
     Radiotherapy for the treatment of malignant pleural mesothelioma.
     Lancet Oncol. 2017;18:e532-e542.
     PubMed     Abstract available
     
     
     
102. MAIO M, Scherpereel A, Calabro L, Aerts J, et al
     Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
     Lancet Oncol. 2017;18:1261-1273.
     PubMed     Abstract available
     
     
     July 2017
103. AKAMATSU H, Takahashi T, Yamamoto N
     Prophylactic cranial irradiation in small-cell lung cancer - Authors' reply.
     Lancet Oncol. 2017;18:e369.
     PubMed    
     
     
     
104. FAN X, Liang F, Zhu J
     Prophylactic cranial irradiation in small-cell lung cancer.
     Lancet Oncol. 2017;18:e368.
     PubMed    
     
     
     
105. WEISS GJ, Lohinai Z
     Prophylactic cranial irradiation in small-cell lung cancer.
     Lancet Oncol. 2017;18:e367.
     PubMed    
     
     
     
106. MANAPOV F, Eze C
     Prophylactic cranial irradiation in small-cell lung cancer.
     Lancet Oncol. 2017;18:e366.
     PubMed    
     
     
     
107. RUSTHOVEN CG, Kavanagh BD
     Prophylactic cranial irradiation in small-cell lung cancer.
     Lancet Oncol. 2017;18:e365.
     PubMed    
     
     
     
108. DEL PAGGIO JC, Sullivan R, Schrag D, Hopman WM, et al
     Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
     Lancet Oncol. 2017;18:887-894.
     PubMed     Abstract available
     
     
     June 2017
109. BROWER V
     Atezolizumab in advanced non-small-cell lung cancer.
     Lancet Oncol. 2017 Jun 22. pii: S1470-2045(17)30504.
     PubMed    
     
     
     
110. FAIVRE-FINN C, Snee M, Ashcroft L, Appel W, et al
     Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
     Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30318.
     PubMed     Abstract available
     
     
     
111. FIETKAU R
     Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer?
     Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30439.
     PubMed    
     
     
     
112. SHAW AT, Kim TM, Crino L, Gridelli C, et al
     Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
     Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30339.
     PubMed     Abstract available
     
     
     May 2017
113. SHAVERDIAN N, Lisberg AE, Bornazyan K, Veruttipong D, et al
     Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
     Lancet Oncol. 2017 May 24. pii: S1470-2045(17)30380.
     PubMed     Abstract available
     
     
     
114. DAS M
     Brigatinib effective in ALK-positive non-small-cell lung cancer.
     Lancet Oncol. 2017 May 11. pii: S1470-2045(17)30342.
     PubMed    
     
     
     March 2017
115. GULLEY JL, Rajan A, Spigel DR, Iannotti N, et al
     Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
     Lancet Oncol. 2017 Mar 31. pii: S1470-2045(17)30240.
     PubMed     Abstract available
     
     
     
116. TAKAHASHI T, Yamanaka T, Seto T, Harada H, et al
     Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
     Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30230.
     PubMed     Abstract available
     
     
     
117. SLOTMAN BJ
     Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer?
     Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30193.
     PubMed    
     
     
     February 2017
118. SCOTT JG, Berglund A, Schell MJ, Mihaylov I, et al
     A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
     Lancet Oncol. 2017;18:202-211.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: